van Houte Hans 4

What Happened

• Hans van Houte, Chief Financial Officer of Nurix Therapeutics (NRIX), received equity awards on February 10, 2026: 93,750 derivative stock options and 42,875 restricted stock units (RSUs). The filing lists $0.00 as the acquisition price because these are company compensation grants, not open-market purchases or sales.

Key Details

• Transaction date: 2026-02-10; transaction type: Award/Grant (code A); reported as derivative awards.
• Award amounts: 93,750 stock options; 42,875 RSUs (total = 136,625 share-equivalents).
• Price shown: $0.00 on the Form 4 (typical for grants reported as awards).
• Shares owned after transaction: not disclosed in this filing.
• Filing timeliness: Reported on the same date (Period of Report 2026-02-10), no late filing flag in the provided data.
• Relevant footnotes:
  • Options vest monthly: 1/36 of total each month beginning March 10, 2026, through Feb 9, 2029, subject to continued service.
  • Each RSU equals a contingent right to one share.
  • RSUs vest quarterly: 1/12 of total each quarter over three years, first vesting on July 30, 2026; shares delivered after vesting.
  • RSUs do not expire; they either vest or are canceled before vest dates.

Context

• These are compensation grants (not purchases or sales) intended to retain and incentivize the CFO; they do not represent immediate cash value until options are exercised or RSUs vest and shares are delivered.
• For retail investors, awarded options and RSUs are common executive compensation—useful to track dilution and alignment but not a direct bullish/bearish market signal by themselves.